651 related articles for article (PubMed ID: 19185785)
21. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
22. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
23. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
24. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
25. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
26. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban for thromboprophylaxis.
Lotke PA
N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009675
[No Abstract] [Full Text] [Related]
28. Rivaroxaban (Xarelto)--a new oral anticoagulant.
Med Lett Drugs Ther; 2011 Aug; 53(1371):65-7. PubMed ID: 21860366
[No Abstract] [Full Text] [Related]
29. Rivaroxaban for thromboprophylaxis.
ten Cate H; Hamulyak K
N Engl J Med; 2008 Nov; 359(20):2174-5; author reply 2176. PubMed ID: 19009676
[No Abstract] [Full Text] [Related]
30. FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery.
Aalbers J
Cardiovasc J Afr; 2011; 22(4):218. PubMed ID: 21881694
[No Abstract] [Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
Gheorghiade M; Thyssen A; Zolynas R; Nadar VK; Greenberg BH; Mehra M; Sun X; Tian H; Plotnikov AN; Burton P
J Heart Lung Transplant; 2011 Feb; 30(2):218-26. PubMed ID: 20947383
[TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
[TBL] [Abstract][Full Text] [Related]
33. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Friedman RJ
Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
[TBL] [Abstract][Full Text] [Related]
34. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
Chen T; Lam S
Cardiol Rev; 2009; 17(4):192-7. PubMed ID: 19525681
[TBL] [Abstract][Full Text] [Related]
36. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
[TBL] [Abstract][Full Text] [Related]
37. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Turpie AG; Fisher WD; Bauer KA; Kwong LM; Irwin MW; Kälebo P; Misselwitz F; Gent M;
J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban, an oral direct factor Xa inhibitor.
Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM
Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993
[TBL] [Abstract][Full Text] [Related]
39. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
[TBL] [Abstract][Full Text] [Related]
40. [Rivaroxaban in the prevention and treatment of thromboembolic disorders].
Helbing T; Bode C; Moser M
Hamostaseologie; 2012; 32(3):195-202. PubMed ID: 22777255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
